Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren's disease Phase III trials

NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1 Data showed consistent improvements across secondary outcome measures, and a favorable safety profile1  Novartis plans to submit to health authorities globally in early 2026 If approved, ianalumab could become first targeted treatment for this heterogeneous, systemic autoimmune disease Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren’s disease, the seco ...